Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

September 14, 2021

Study Completion Date

August 31, 2026

Conditions
Melanoma
Interventions
DRUG

Fecal Microbial Transplantation

"All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017."

Trial Locations (3)

N6A 5W9

London Regional Cancer Program, London

H2X 0C1

CHUM, Montréal

H3T 1E2

Jewish General Hospital, Montreal

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER